FOXL2 (Polyclonal), RPab

Summary and Explanation

FOXL2 antibody is a relatively sensitive and highly specific marker for Sex Cord-Stromal Tumors (SCST). FOXL2 antibody expression is present in almost all SCSTs with a FOXL2 mutation or without a mutation. A specific somatic mutation in the FOXL2 gene has been found in Adult Granulosa Cell Tumor (402C→G / C134W), which is present in 70-95% of Ovarian Adult Granulosa Cell Tumors but not in Ovarian Fibromas. This mutation is also present in 2 of 5 men with Adult Granulosa Cell Tumor but absent in Ovarian Juvenile Granulosa Cell Tumors. Studies have demonstrated that FOXL2 is expressed in Cervical Squamous Cancer. FOXL2 suppresses the proliferation and promotes apoptosis of Cervical Cancer cells mainly through decreasing Ki-67 expression and increasing Fas ligand expression. FOXL2 has also been found to restrain the invasiveness of Cervical Cancer cells; hence, FOXL2 might be a novel tumor suppressor in Cervical Cancer. A study has demonstrated that FOXL2 antibody is expressed in Breast Cancer and influences clinical outcome with improved recurrence-free survival in cases with nuclear expression. In a multivariate Cox model, nuclear FOXL2 was a significant prognostic factor in ER-positive patients treated with tamoxifen and tumors expressing nuclear FOXL2 were also more likely positive for stromal and/or cytoplasmic aromatase.